Dr Mikhail raised questions about our article on the treatment of patients with diabetes with extended-release nicotinic acid (niacin).1 First, he correctly noted that there were mistakes in linking reference numbers in the text to those in the reference list. Unfortunately, in the final editing process, errors occurred that were not identified, so some references are misnumbered. Second, he emphasized that the study should not be generalized to include niacin therapy in all patients with diabetes. Certainly all patients with diabetes are not candidates for niacin therapy. As pointed out by the National Cholesterol Education Program,2 the primary aim of lipid-lowering therapy in patients with diabetes is to achieve goals for low-density lipoprotein cholesterol level. Thereafter, consideration can be given to adding other lipid-lowering agents to achieve goals for non–high-density lipoprotein cholesterol levels and to favorably modify atherogenic dyslipidemia (high triglyceride and low high-density lipoprotein levels).
Grundy SM. The Use of Niacin in Diabetes Mellitus—Reply. Arch Intern Med. 2003;163(3):370. doi:10.1001/archinte.163.3.369-a